Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Clovis Oncology Inc (CLVS) USD0.001

Sell:$5.14 Buy:$5.15 Change: $0.20 (3.75%)
NASDAQ:0.11%
Market closed |  Prices as at close on 18 September 2019 | Switch to live prices |
Sell:$5.14
Buy:$5.15
Change: $0.20 (3.75%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 18 September 2019 | Switch to live prices |
Sell:$5.14
Buy:$5.15
Change: $0.20 (3.75%)
Market closed |  Prices as at close on 18 September 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Contact details

Address:
5500 Flatiron Pkwy Unit 100
BOULDER
80301-2834
United States
Telephone:
+1 (303) 6255000
Website:
www.clovisoncology.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CLVS
ISIN:
US1894641000
Market cap:
$291.87 million
Shares in issue:
54.66 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Ginger Graham
    Chairman of the Board
  • Patrick Mahaffy
    President, Chief Executive Officer, Co-Founder, Director
  • Gillian Ivers-Read
    Co-Founder, Executive Vice President, Chief Regulatory Officer
  • Daniel Muehl
    Executive Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
  • Paul Gross
    Executive Vice President, Chief Compliance Officer, General Counsel
  • Ann Bozeman
    Executive Vice President of Human Resources
  • Lindsey Rolfe
    Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.